BioInvent

About BioInvent

BioInvent International AB is a clinical-stage biotechnology company headquartered in Lund, Sweden, specializing in the discovery and development of novel antibody-based immunotherapies for cancer treatment. The company was founded in 1997, building on expertise in immunology, cancer biology, and antibody biology, and was listed on the Stockholm Stock Exchange in 2001. A significant transformation began in 2018 with the appointment of Martin Welschof as CEO, shifting the company's focus entirely to immuno-oncology and implementing a robust portfolio strategy.

At the core of BioInvent's operations is its proprietary, patient-centric technology platform. This includes the F.I.R.S.T™ screening tool, which uniquely identifies both disease-associated targets and the specific antibodies that bind to them directly from patient-derived materials. This process is powered by the n-CoDeR® antibody library, a vast collection of over 30 billion human antibody genes, enabling the rapid generation of promising new drug candidates. This integrated platform allows the company to build its own clinical pipeline and engage in licensing and partnership opportunities.

BioInvent's business model is multi-faceted, primarily driven by the advancement of its clinical and preclinical development projects. Revenue is generated through strategic research collaborations and license agreements with major pharmaceutical companies, including Pfizer, Exelixis, Merck, and AstraZeneca. A key asset is its in-house, state-of-the-art manufacturing facility, operational since 1988, which not only supports its own clinical trials but also provides contract manufacturing services to external parties. The company's pipeline includes multiple drug candidates in Phase 1/2 trials for treating both hematological cancers and solid tumors, such as BI-1808 for solid tumors and BI-1206 for Non-Hodgkin's Lymphoma.